CASI taps up CR Guokang for Evomela distribution in China



U.S.-based, China focused CASI Pharmaceuticals Inc., (Nasdaq.CASI) announced the signing of an exclusive distribution agreement with China Resources Guokang Pharmaceuticals Co., Ltd, (CRGK), focused on Evomela (melphalan hydrocholoride). China’s National Medical Products Administration (NMPA) issued a market approval to Evomela in December, indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma (MM), and the palliative treatment of patients with MM for whom oral therapy is not appropriate.

No financial specifics related to the deal were disclosed. CRGK is a state-owned distributor with extensive national distribution network. Melphalan is a chemotherapy drug that belongs to the class of nitrogen mustard alkylating agents. The oral formulation of the drug was first brought to China by GlaxoSmithKline in 2001, and currently Aspen Pharmacare Australia is the only firm that markets the molecule in China. CASI’s injectable formulation is the only form of melphalan suitable for use in the high-dose conditioning indication in pre-transplant therapy.


Reference:

Related news
U.S.-based, China market-focused CASI Pharmaceuticals (NASDAQ: CASI) announced receipt of National Medical Products Administration (NMPA) approval for Marqibo (a liposome formulation of vincristine sulfate) to enter a registrational clinical trial in China. CASI licensed Greater China development rights to Marquibo from U.S. firm Spectrum Pharmaceuticals signed in September 2014, and reported by GBI.
  • 1552010024406
  • China
  • Drug
Marketing approvals for Switzerland-based Roche’s hemophilia treatment Hemcibra (emicizumab) and South Africa-based Aspen’s cancer drug Alkeran (melphalan) were recently published by Cuba’s Center for State Control of Drugs and Medical Devices (CECMED).
U.S.-based, China-focused CASI Pharmaceuticals Inc., (Nasdaq.CASI) trumpeted market approval from China’s National Medical Products Administration (NMPA) for Evomela (melphalan hydrochloride).
  • 1543889259317
  • China
  • Drug
U.S.-based, China-operating CASI Pharmaceuticals Inc., (Nasdaq:CASI) announced a private placement of shares has been completed, raising USD 48.5 million.
U.S.-based pharma firm CASI Pharmaceuticals Inc., (Nasdaq: CASI) announced the receipt of a USD 50 million private placement of stock and warrants that will fund the launch of its first commercial product in China, which is expected imminently.
Recent news
Alfonso Ramírez Cuéllar, president of the Budget Commission in Mexico’s House of Representatives, urged the Ministry of Finance and Public Credit (SHCP) to disclose the names of 10 pharmaceutical companies that have received contracts for 80% of the consolidated drug purchases during previous administrations.
Colombia’s National Food and Drug Surveillance Institute (INVIMA) last month approved Switzerland-based Roche’s hemophilia drug Hemlibra (emicizumab), as GBI analysis found.
France-based Sanofi-Aventis saw its diabetes drug Soliqua (insulin glargine + lixisenatide) obtain registration from Colombia’s National Food and Drug Surveillance Institute (INVIMA), according to GBI analysis.
According to GBI analysis, Ecuador’s National Agency for Health Regulation, Control and Surveillance (ARCSA) last month granted registration to Switzerland-based Ferring’s oral anti-inflammatory Cortiment (budesonide).
Switzerland-based giant Novartis AG has officially launched its Ultibro (indacaterol glycopyrronium bromide, powder for inhalation, hard capsules) and Seebri (glycopyrronium bromide, powder for inhalation, hard capsules) chronic obstructive pulmonary disease (COPD) maintenance therapies into the Chinese market.
  • 1552880244053
  • China
  • Drug
Sino-U.S. biotech Xynomic Pharma announced the receipt of clinical trial approvals in China, Spain, and Poland for its histone deacetylase (HDAC) inhibitor abexinostat in combination with pazopanib for patients with renal cell carcinoma (RCC).
  • 1552879902162
  • China
  • Drug
China-based vaccines specialist CanSino Biotechnology Inc., is moving to hold an initial public offering (IPO) of 5,725,200 H shares to the Hong Kong Stock Exchange (HKSE) Main Board from March 28, 2019 alongside another 51,523,400 H shares to the global market, with the price range currently at HKD 21 to HKD 22 per share.
Analytics Snapshot


Understand the facts and anticipate market shifts. Get the facts here.